← ANALYST RATINGS · TIPRANKS
West Pharmaceutical Services (WST): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $418, the highest $440, the lowest $400. The average is +8.9% from the last price of $384.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $410 → $420+2.4% | Buy | +9.4% | Reiterated | 13.10.26on TipRanks 09:00 | +1.2%next day +1.8% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $400 → $440+10.0% | Buy | +14.6% | Reiterated | 07.10.26on TipRanks 03:55 | −1.4%next day −0.5% · 5 days +3.2% | ↗ |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $365 → $400+9.6% | Buy | +4.2% | Upgrade | 22.09.26on TipRanks 06:15 | +2.6%next day +2.0% · 5 days +2.7% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $340 → $415+22.1% | Buy | +8.1% | Reiterated | 09.09.26on TipRanks Sep 14 09:30 | +0.2%next day +2.8% · 5 days +8.5% | ↗ |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $425 → $400−5.9% | Buy | +4.2% | Upgrade | 20.08.26on TipRanks 00:05 | — | |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $400 → $412+3.0% | Buy | +7.3% | Reiterated | 03.08.26on TipRanks 06:45 | +0.6%next day −1.6% · 5 days −0.8% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $410 → $425+3.7% | Buy | +10.7% | Reiterated | 27.07.26on TipRanks 14:12 | +0.9%next day +1.5% · 5 days +2.6% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $410 | Buy | +6.8% | Reiterated | 24.07.26on TipRanks 10:30 | −7.8%next day +0.9% · 5 days +2.9% | ↗ |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $413 → $416+0.7% | Buy | +8.3% | Reiterated | 23.07.26on TipRanks 21:04 | — | |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $406 → $410+1.0% | Buy | +6.8% | Reiterated | 23.07.26on TipRanks 21:04 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $390 → $392+0.5% | Hold | +2.1% | Reiterated | 23.07.26on TipRanks 21:04 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $417 → $412−1.2% | Buy | +7.3% | Reiterated | 23.07.26on TipRanks 21:04 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $410 → $409−0.2% | Buy | +6.5% | Reiterated | 23.07.26on TipRanks 21:04 | — | |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 23.07.26on TipRanks 21:04 | −7.8%next day +0.9% · 5 days +2.9% | ↗ |
| Curtis Moiles★★★★★★★★★★#10894 · hits 0% · avg −24.8% | Exane BNP Paribas | $447 | Buy | +16.4% | Initiated | 13.07.26on TipRanks 07:46 | +2.5%next day −0.9% · 5 days −1.1% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $350 → $390+11.4% | Buy | +1.6% | Reiterated | 02.07.26on TipRanks 06:35 | +0.3%next day −3.1% · 5 days −4.7% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | $375 | Buy | −2.3% | Assigned | 01.06.26on TipRanks 16:15 | −1.4%next day +2.0% · 5 days +10.2% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $355 → $340−4.2% | Buy | −11.5% | Reiterated | 13.02.26on TipRanks 09:40 | +2.8%next day −3.1% · 5 days −2.6% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $310 → $315+1.6% | Buy | −18.0% | Reiterated | 13.02.26on TipRanks 08:45 | +2.8%next day −3.1% · 5 days −2.6% | ↗ |
| David Windley★★★★★★★★★★#769 · hits 59% · avg +9.3% | Jefferies | $365 → $295−19.2% | Buy | −23.2% | Reiterated | 10.02.26on TipRanks 09:05 | −1.9%next day +1.1% · 5 days +2.8% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $320 | Buy | −16.7% | Reiterated | 28.01.26on TipRanks 03:45 | −1.8%next day −1.2% · 5 days +1.8% | ↗ |
| Thomas DeBourcy★★★★★★★★★★#7610 · hits 100% · avg +34.1% | Nephron | $367 | Buy | −4.4% | Upgrade | 11.12.25on TipRanks 07:35 | +1.9%next day −0.8% · 5 days +0.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering West Pharmaceutical Services
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $415 at a price of $371 (+11.9%); now: $417 at $384 (+8.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Buy | 9 | 11 | 16 | 12 | 11 | 4 |
| Hold | 7 | 8 | 5 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.20 (from $2.16 to $2.27). Last quarter: $2.37.
Sales
Next quarter’s sales estimate — $827M (from $821M to $836M). Last quarter: $872M.
Best top-analyst consensus in the sector · Healthcare
About West Pharmaceutical Services
- CEO: Michel Lagarde
- Employees: 10,800
- 530 Herman O. West Drive, Exton, PA, 19341-1147, US
- www.westpharma.com
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedi
Data from the stock’s TipRanks forecast page, read 82 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗